U.S. Markets closed

Immunomedics: Epratuzumab study shows improvement of therapy after R-CHOP

Immunomedics reported that adding two doses of epratuzumab labeled with the radioisotope, yttrium-90, 90Y, to a combination of rituximab and CHOP chemotherapy, R-CHOP, the standard of care for patients with diffuse large B-cell lymphoma,DLBCL, appeared to improve elderly patients' responses to treatment.